


PRODUCT INFORMATION



1-Stearoyl-d₃₅-2-hydroxy-sn-glycero-3-PC Item No. 28230

CAS Registry No.: 327178-92-7
Formal Name: 4,7R-dihydroxy-N,N,N-trimethyl-10-oxo-3,5,9-trioxa-4-phosphaheptacosan-11,11,12,12,13,13,14,14,15,15,16,16,17,17,18,18,19,19,20,20,21,21,22,22,23,23,24,24,25,25,26,26,27,27,27-d₃₅-1-aminium-10-¹⁴C, 4-oxide, inner salt
Synonyms: S-Lyso-PC-d₃₅, 1-Stearoyl-d₃₅-2-hydroxy-sn-glycero-3-Phosphocholine, 1-Stearoyl-d₃₅-2-lyso-sn-glycero-3-PC
MF: C₂₆H₁₉D₃₅NO₇P
FW: 558.9
Chemical Purity: ≥98% (1-Stearoyl-2-hydroxy-sn-glycero-3-PC)
Deuterium Incorporation: ≥99% deuterated forms (d₁-d₃₅); ≤1% d₀
Supplied as: A solid
Storage: -20°C
Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

1-Stearoyl-d₃₅-2-hydroxy-sn-glycero-3-PC is intended for use as an internal standard for the quantification of 1-stearoyl-2-hydroxy-sn-glycero-3-PC (Item No. 15107) by GC- or LC-MS. The accuracy of the sample weight in this vial is between 5% over and 2% under the amount shown on the vial. If better precision is required, the deuterated standard should be quantitated against a more precisely weighed unlabeled standard by constructing a standard curve of peak intensity ratios (deuterated versus unlabeled).

1-Stearoyl-d₃₅-2-hydroxy-sn-glycero-3-PC is supplied as a solid. A stock solution may be made by dissolving the 1-stearoyl-d₃₅-2-hydroxy-sn-glycero-3-PC in the solvent of choice, which should be purged with an inert gas. 1-Stearoyl-d₃₅-2-hydroxy-sn-glycero-3-PC is soluble in the organic solvent ethanol at a concentration of approximately 2 mg/ml. 1-Stearoyl-d₃₅-2-hydroxy-sn-glycero-3-PC is soluble in a 1:1 solution of chloroform:methanol.

Description

1-Stearoyl-2-hydroxy-sn-glycero-3-PC is a saturated lysophosphatidylcholine. It increases IL-1 β production in isolated human blood monocytes when used at a concentration of 12.5 μ M.¹ Plasma levels of 1-stearoyl-2-hydroxy-sn-glycero-3-PC are decreased in patients with lung cancer.²

References

1. Liu-Wu, Y., Hurt-Camejo, E., and Wiklund, O. Lysophosphatidylcholine induces the production of IL-1 β by human monocytes. *Atherosclerosis* **137**(2), 351-357 (1998).
2. Dong, J., Xiaoming, C., Zhao, L., et al. Lysophosphatidylcholine profiling of plasma: Discrimination of isomers and discovery of lung cancer biomarkers. *Metabolomics* **6**(4), 478-488 (2010).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 12/05/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM